Search company, investor...

Predict your next investment

Bristol-Myers Squibb company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
bms.com

Investments

66

Portfolio Exits

14

Partners & Customers

10

Service Providers

1

About Bristol-Myers Squibb

Bristol-Myers Squibb (NYSE: BMY) is a global biopharmaceutical company committed to discovering, developing, and delivering medicines that help patients prevail over serious diseases. The company was founded in 1887 and is based in New York, New York.

Headquarters Location

430 E. 29th Street 14th Floor

New York, New York, 10016,

United States

800-332-2056

Want to inform investors similar to Bristol-Myers Squibb about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Bristol-Myers Squibb

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Bristol-Myers Squibb in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Research containing Bristol-Myers Squibb

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Bristol-Myers Squibb in 2 CB Insights research briefs, most recently on Oct 28, 2022.

Latest Bristol-Myers Squibb News

NICE recommends Bristol-Myers Squibb’s mavacamten

Jun 5, 2023

Approximately 7,000 people will now be able to choose this treatment for obstructive HCM on the NHS. Bristol-Myers Squibb’s mavacamten will be used to treat obstructive hypertrophic cardiomyopathy. Credit: Africa Studio via Shutterstock.com. The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending the use of Bristol-Myers Squibb’s mavacamten (Camzyos) as an add-on to standard care to control symptoms of  obstructive hypertrophic cardiomyopathy (HCM). The symptoms of obstructive HCM include fatigue, palpitations and shortness of breath. Recommended Reports Camzyos is an allosteric and reversible inhibitor that is selective for cardiac myosin. It has also been approved in the US to treat symptomatic New York Heart Association class II-III obstructive HCM in adult patients, improving their functional capacity and symptoms. The combination of mavacamten and standard care was found to be more effective than standard care alone and could prevent or delay the need for invasive surgery. NICE medicines evaluation director Helen Knight stated: “Obstructive hypertrophic cardiomyopathy is a disease for which, until now, there has been no specific treatment that targets its underlying cause. “It has a very high and wide-ranging impact on quality of life and because it can develop at any age, it can occur in younger people who may formerly have had very active lifestyles. “The treatments currently used to try to manage symptoms are associated with side effects and are often ineffective. “We’re therefore pleased to be able to recommend a treatment that has the potential to alter the course of obstructive hypertrophic cardiomyopathy and offer greater hope to people with it.” In April 2023, the European Medicines Agency’s committee for medicinal products for human use recommended approval of Camzyos for the same indication. Share this article

Bristol-Myers Squibb Investments

66 Investments

Bristol-Myers Squibb has made 66 investments. Their latest investment was in TORL BioTherapeutics as part of their Series B on April 4, 2023.

CBI Logo

Bristol-Myers Squibb Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/13/2023

Series B

TORL BioTherapeutics

$158M

Yes

2

3/15/2023

Series A - II

Mediar Therapeutics

$85M

Yes

6

2/10/2023

Series A - II

Allyx Therapeutics

$2.31M

No

1

1/26/2023

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

11/29/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/13/2023

3/15/2023

2/10/2023

1/26/2023

11/29/2022

Round

Series B

Series A - II

Series A - II

Series A - II

Series A

Company

TORL BioTherapeutics

Mediar Therapeutics

Allyx Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$158M

$85M

$2.31M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

6

1

10

10

Bristol-Myers Squibb Portfolio Exits

14 Portfolio Exits

Bristol-Myers Squibb has 14 portfolio exits. Their latest portfolio exit was Personal Genome Diagnostics on December 23, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/23/2021

Acquired

$99M

12

10/1/2021

IPO

$99M

Public

3

8/18/2021

Acquired

$99M

36

3/26/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/3/2021

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/23/2021

10/1/2021

8/18/2021

3/26/2021

2/3/2021

Exit

Acquired

IPO

Acquired

IPO

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

12

3

36

10

10

Bristol-Myers Squibb Acquisitions

18 Acquisitions

Bristol-Myers Squibb acquired 18 companies. Their latest acquisition was Turning Point Therapeutics on August 17, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/17/2022

Series D

$99M

$144.43M

Acq - P2P

5

11/17/2020

Series B

$99M

$94M

Acq - P2P

8

8/24/2020

Series C

$99M

$18.8M

Acquired

10

11/21/2019

Subscribe to see more

$99M

Subscribe to see more

10

8/3/2017

Other Venture Capital

Subscribe to see more

$99M

$99M

Subscribe to see more

10

Date

8/17/2022

11/17/2020

8/24/2020

11/21/2019

8/3/2017

Investment Stage

Series D

Series B

Series C

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$144.43M

$94M

$18.8M

$99M

Note

Acq - P2P

Acq - P2P

Acquired

Subscribe to see more

Subscribe to see more

Sources

5

8

10

10

10

Bristol-Myers Squibb Partners & Customers

10 Partners and customers

Bristol-Myers Squibb has 10 strategic partners and customers. Bristol-Myers Squibb recently partnered with ONO PHARMACEUTICAL CO on May 5, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

5/16/2023

Partner

Japan

Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial

NEW YORK -- Personalis said Tuesday that it has partnered with Ono Pharmaceutical and Japan 's National Cancer Center to assess its minimal residual disease platform in a study of Opdivo in resectable rectal cancer with mismatch repair deficiency .

1

4/20/2023

Licensor

Germany

Evotec : Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb

Evotec-partner Tubulis GmbH and Bristol Myers Squibb today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates .

9

4/11/2023

Partner

United States

Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib

Foundation Medicine said it expanded collaboration with Bristol Myers Squibb to develop a tissue-based test FoundationOne CDx , as a companion diagnostic for Bristol Myers Squibb ' investigational oral cancer drug repotrectinib .

2

3/20/2023

Licensor

United Kingdom

Subscribe to see more

Subscribe to see more

10

3/2/2023

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

5/16/2023

4/20/2023

4/11/2023

3/20/2023

3/2/2023

Type

Partner

Licensor

Partner

Licensor

Partner

Business Partner

Country

Japan

Germany

United States

United Kingdom

United States

News Snippet

Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial

NEW YORK -- Personalis said Tuesday that it has partnered with Ono Pharmaceutical and Japan 's National Cancer Center to assess its minimal residual disease platform in a study of Opdivo in resectable rectal cancer with mismatch repair deficiency .

Evotec : Partner Tubulis Announces Strategic License Agreement with Bristol Myers Squibb

Evotec-partner Tubulis GmbH and Bristol Myers Squibb today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates .

Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib

Foundation Medicine said it expanded collaboration with Bristol Myers Squibb to develop a tissue-based test FoundationOne CDx , as a companion diagnostic for Bristol Myers Squibb ' investigational oral cancer drug repotrectinib .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

9

2

10

10

Bristol-Myers Squibb Service Providers

1 Service Provider

Bristol-Myers Squibb has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Bristol-Myers Squibb Team

165 Team Members

Bristol-Myers Squibb has 165 team members, including current Founder, President, Suresh Poosala.

Name

Work History

Title

Status

Suresh Poosala

National Institutes of Health, and St. Jude Children's Research Hospital

Founder, President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Suresh Poosala

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

National Institutes of Health, and St. Jude Children's Research Hospital

Title

Founder, President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Bristol-Myers Squibb to Competitors

B
BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.

D
DoubleRainbow Biosciences

DoubleRainbow Biosciences develops technologies rooted in the mechanistic understanding of specialized metabolic systems in plants and other organisms. The firm devises biosynthetic strategies that provide sustainable access to high-value natural products of medicinal or industrial significance.

L
Luminary Therapeutics

Luminary is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with cell engineering to overcome antigen escape and T-cell dysfunction. Its therapeutic solutions include BAFF CAR-T, Universal Receptor, and a non-viral allogeneic platform. The company was founded in 2019 and is based in Minneapolis, Minnesota.

G
GI Innovation

GI Innovation is a bio-venture company that explores the development of new drugs through the combination of microbiome (human microorganism) and protein drugs.

K
Kangpu Biomedical

Kangpu Biomedical is a biopharmaceutical company in the clinical stage, focusing on cancer, autoimmune diseases, inflammation, and other therapeutic areas, mainly based on protein ubiquitination and the degradation and X-Synergy new drug combination technology platform and other proprietary patents.

I
Immunwork

Immunwork is a pharmaceutical company that focuses on the research, development, and commercialization of new drugs based on its technology platform for treating multiple types of cancer, autoimmune diseases, osteoporosis, and other severe clinical conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.